Dare Bioscience Inc. (DARE) 12-Month Stock Forecast & Price Target Cone

Per the Roarable RQD rating, DARE scores 36 out of 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 6/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 7/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 11/20 (Altman Z 2.5; Piotroski F 4/9; Debt/Equity 0.5). The weakest pillars are Insider Conviction and Whale/Flow, which together indicate limited evidence of insider or institutional conviction in the source data. The cash engine score reflects negative returns on capital and zero free-cash-flow yield, meaning the company is not currently generating cash returns relative to its capital base. The balance-sheet pillar is the strongest of the five, but it is still below mid-range. For a prospective investor, the rating points to elevated risk, a weak operating cash profile, and limited measurable upside drivers within the provided data. Valuation tradeoffs are difficult to assess because P/E and EV/EBITDA are not available in source data, so the stock's price of $0.68 cannot be benchmarked against earnings. Any upside case would depend on developments not captured in this dataset.

Per the SEC financials, the company has reported operating and net losses across all three listed periods, with operating margin of -60% and net margin of -60% in the market data. ROIC is -35%. The forensic balance sheet pillar cites an Altman Z-Score of 2.5 and a Piotroski F-Score of 4/9. Debt/Equity is 0.5 per the Roarable RQD rating. Reported cash was $24.7M at FY 2025, up from $15.7M at FY 2024.

The news wire contains six items, all tagged as market-wire content with YELLOW signal status. The most specific catalyst headline reports that Dare Bioscience secured a $1.5M funding boost for DARE-LARC, per GuruFocus. A Stock Titan item describes an implant designed to replace months to years of repeat injections. Other items (Yahoo Finance, TradingView, Benzinga) are generic quote or market-action pages without specific fundamental detail. Risk watch items include the small $13.4M market capitalization, the 52-week low of $0.63 against the current $0.68 price, and the negative operating and FCF trend. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, supply chain: NONE; butterfly links: none; proprietary signals: none. No upstream or downstream dependencies, sector correlations beyond the stated Health Care classification, or second-order bottlenecks are identified in the source data. Investors should note that the absence of mapped links means this dataset cannot identify ripple effects from partners, suppliers, or customers.

• What specific products or pipeline assets generate the reported $1.0M in revenue, and what are the regulatory milestones ahead?
• What is the company's debt position, given that debt is listed as N/A in every reported period while Debt/Equity is cited as 0.5?
• What is the cash runway implied by the $24.7M FY 2025 cash balance against the $-10.3M FCF burn?
• What are the terms and dilution implications of the $1.5M funding referenced in the news wire?
• Why is EPS, P/E, and EV/EBITDA unavailable, and what would be needed to benchmark the $0.68 price against earnings?